Rhythm pharmaceuticals, inc. (RYTM)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Sep'16
Operating expenses:
Research and development

22,504

24,809

26,572

35,308

22,761

18,762

10,705

8,584

12,286

6,653

5,971

5,397

4,873

5,419

Selling, general, and administrative

12,796

9,415

10,535

8,841

7,759

8,389

8,539

6,437

4,715

4,330

2,315

1,357

1,516

982

Total operating expenses

35,300

34,224

37,107

44,149

30,520

27,151

19,244

15,021

17,001

10,983

8,286

6,754

6,389

6,401

Loss from operations

-35,300

-34,224

-37,107

-44,149

-30,520

-27,151

-19,244

-15,021

-17,001

-10,983

-8,286

-6,754

-6,389

-6,401

Other income (expense):
Revaluation of Series A Investor Instrument and Series A Investor Right/Obligation

-

-

-

-

-

-

-

-

-

-

-1,781

-82

-

-

Interest income, net

1,136

1,268

1,104

1,353

1,546

1,644

1,558

609

542

452

51

34

29

10

Total other income, net

1,136

1,268

1,104

1,353

1,546

1,644

1,558

609

542

452

-1,730

-48

29

10

Net loss

-34,164

-32,956

-36,003

-42,796

-28,974

-25,507

-17,686

-14,412

-16,459

-10,531

-10,016

-6,802

-6,360

-6,391

Net loss attributable to common stockholders

-

-

-36,003

-42,796

-

-25,507

-17,686

-14,412

-16,459

-10,619

-11,429

-8,008

-7,526

-7,191

Net loss per share attributable to common stockholders, basic and diluted

-0.78

-0.74

-1.04

-1.24

-0.84

-0.74

-0.52

-0.52

-0.60

0.48

-1.78

-0.79

-0.74

-0.71

Weighted-average common shares outstanding, basic and diluted

44,049

42,278

34,541

34,452

34,417

34,514

34,256

27,960

27,284

26,275

6,404

10,196

10,196

10,196

Other comprehensive loss:
Net loss

-34,164

-

-

-

-28,974

-

-

-

-

-

-

-

-

-

Unrealized gain on marketable securities

63

-

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-34,101

-

-

-

-28,974

-

-

-

-

-

-

-

-

-